Abel Costa Neto

Dr. Abel Costa Neto

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
César Alexander Ortiz RojasCésar Alexander Ortiz Rojas
César Alexander Ortiz Rojas
ANAbel Costa Neto
Abel Costa Neto
DPDiego A Pereira-Martins
Diego A Pereira-Martins
DLDuy Minh Le
Duy Minh Le
DSDominique Sternadt
Dominique Sternadt
EREduardo Rego
Eduardo Rego
Several laboratory and clinical variables have been reported to be associated with the outcome of intensive chemotherapy for acute myeloid leukemia (AML), but only a few have been tested in the context of hematopoietic stem cell transplant (HSCT). This study aimed to identify genes whose expression of AML at diagnosis were associated with survival after HSCT. For this purpose, three publicly available adult AML cohorts (TCGA, BeatAML, and HOVON), whose patients were treated with intensive chemotherapy and then subjected to allogeneic or autologous HSCT, were included in this study. After whole transcriptome analysis, we identified ME1 as the only gene whose high expression was associated with shorter survival in patients subjected to HSCT. In addition, the inclusion of ME1 expression was able to improve the European LeukemiaNet risk stratification. Pathways related to lipid biosynthesis, mainly fatty acids, and cholesterol were positively correlated with ME1 expression. Furthermore, ME1 expression was associated with an M2 macrophage-enriched microenvironment, mature AML blasts hierarchy, and oxidative phosphorylation metabolism. Therefore, ME1 expression can be used as biomarker of poor response to HSCT in AML.

18 July 2025 in Blood Global Hematology
Verified
Journal Article
Open access
VPVerena Pfister
Verena Pfister
FMFernanda de Morais Marques
Fernanda de Morais Marques
TSTalita Silveira
Talita Silveira
JFJayr Schmidt Filho
Jayr Schmidt Filho
VMVinicius Campos de Molla
Vinicius Campos de Molla
CACelso Arrais-Rodrigues
Celso Arrais-Rodrigues

8 January 2026 in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Verified
Journal Article
Open access
PDF file
ASAnderson João Simione
Anderson João Simione
CSCinthya Correa da Silva
Cinthya Correa da Silva
AVAfonso Celso Vigorito
Afonso Celso Vigorito
AMAntonio Vaz Macedo
Antonio Vaz Macedo
HNHeliz Regina Alves das Neves
Heliz Regina Alves das Neves
FDFernando Barroso Duarte
Fernando Barroso Duarte
The development of the Brazilian Registry of Hematopoietic Cell Transplantation (Registro Brasileiro de Transplantes de Células Hematopoieticas), in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR), continues to provide a comprehensive assessment of hematopoietic cell transplantation (HCT) activity and outcomes in Brazil. In this study, we report an updated analysis of national transplant activity. Brazilian transplant centers report their data to the CIBMTR using the FormsNet3 platform, and data are returned to the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea) through the Data Back to Centers (DBtC) tool. Data from patients who underwent HCT from 2015 to 2025 in Brazilian centers were extracted from the CIBMTR. Descriptive analyses were performed using patient-, disease-, and transplant-related variables, and overall survival was estimated using the Kaplan–Meier method. A total of 15,586 HCTs were included (7,507 autologous and 8,079 allogeneic). For survival analyses, 9,150 patients who underwent a first HCT from 2015 to 2023 were analyzed, with a median follow-up of 35 months. The number of reporting centers increased over time, reaching 51 centers during the study period. Acute leukemias remained the most common indication for allogeneic HCT, while multiple myeloma and lymphomas predominated in autologous HCT. In recent years, mismatched related donors have accounted for the largest proportion of allogeneic transplants. Bone marrow was the main graft source in pediatric patients, whereas peripheral blood predominated in adults. Infections were the most frequent cause of death within the first 100 days after HCT, while primary disease was the leading cause beyond 100 days. Survival patterns varied according to disease characteristics and transplantrelated factors, with lower survival estimates observed in patients transplanted with advanced disease stages. Comparisons with the United States Summary Slides suggest both similarities and differences in transplant activity and outcomes, which should be interpreted with caution given variations in data structure, patient characteristics, and risk stratification.

27 August 2026 in British Journal of Haematology
Verified
Journal Article
Open access
ECEdvan Crusoe
Edvan Crusoe
GRGlaciano Ribeiro
Glaciano Ribeiro
JFJoão Tadeu D. Souto Filho
João Tadeu D. Souto Filho
JFJayr Schmidt Filho
Jayr Schmidt Filho
NSNatalia Schutz
Natalia Schutz
GBGbram
Gbram

8 January 2026 in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Verified
Journal Article
Open access
PDF file
CSCinthya Corrêa da Silva
Cinthya Corrêa da Silva
ASAnderson João Simione
Anderson João Simione
GFGiancarlo Fatobene
Giancarlo Fatobene
JFJayr Schmidt Filho
Jayr Schmidt Filho
ASAdriana Seber
Adriana Seber
FDFernando Barroso Duarte
Fernando Barroso Duarte
Objective: To describe CAR-T cell therapy activity and outcomes reported by Brazilian centers participating in the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO)/Center for International Blood and Marrow Transplant Research (CIBMTR) network between January 2020 and December 2025. Methods: Data from patients who received commercial or academic CAR-T cell therapies in Brazilian centers were extracted from the CIBMTR database. Participating centers reported data through the FormsNet3 platform, allowing standardized collection of patient, disease, and treatment-related variables. Descriptive analyses were performed, and overall survival (OS) was estimated using the Kaplan–Meier method. Results: A total of 219 CAR-T cell infusions were reported. The median age was 57 years (range, 4–83 years). The most common indications were non Hodgkin lymphoma (NHL) (146 patients, 67%), multiple myeloma (MM) (39 patients, 18%), acute lymphoblastic leukemia (ALL) (32 patients, 14%), and chronic lymphocytic leukemia (CLL) (2 patients, 1%). Commercial CAR-T products accounted for 89% of all treatments and were predominantly used for NHL (n = 135) and MM (n = 35). Most deaths were attributed to disease progression or relapse (n = 42), followed by infections (n = 14). After a median followup of 365 days, the 1-year OS was 63% (95% CI, 54–73%) among patients with NHL and 73% (95% CI, 57–93%) among patients with ALL. Conclusion: This report documents the implementation and rapid expansion of CAR-T cell therapy in Brazil among centers reporting to the SBTMO/CIBMTR network. The continued development of this collaborative infrastructure supports national monitoring of CAR-T activity, facilitates outcome assessment, and contributes to quality assurance, benchmarking initiatives, and compliance with national and international regulatory requirements.

24 September 2025 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
FMFernanda de Morais Marques
Fernanda de Morais Marques
VPVerena Pfister
Verena Pfister
FPFlavia Parra
Flavia Parra
LPLeila Perobelli
Leila Perobelli
VBValeria Buccheri
Valeria Buccheri
CACelso Arrais-Rodrigues
Celso Arrais-Rodrigues
The Brazilian Group of CLL (BGCLL) has proposed a more restrictive approach for treatment initiation compared to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines. Here, we report on the safety and efficacy of this strategy. We performed a retrospective analysis of patients with CLL registered in the Brazilian CLL Registry between January 2009 and July 2023 who met the minimum data availability criteria for analysis. The BGCLL criteria employ stricter thresholds for cytopenias, defining them as hemoglobin levels below 9.5 g/dL or platelet counts below 50,000/mm3, as opposed to the IWCLL criteria of below 10 g/dL and below 100,000/mm3, respectively. Furthermore, the BGCLL criteria do not consider progressive lymphocytosis or disease-related symptoms to be criteria for treatment initiation when cytopenias or symptomatic masses are absent. Survival outcomes were estimated using the Kaplan–Meier method and compared with log-rank tests. Cox proportional hazards models were used for multivariable analysis, with results expressed as hazard ratios and 95% confidence intervals. A P-value <0.05 was considered statistically significant. A total of 2511 patients were enrolled from 41 centers. Of these, 1404 patients (56%) met the IWCLL criteria for treatment initiation (liberal criteria), whereas only 788 patients (31%) met the BGCLL criteria (restrictive criteria). Patients with liberal criteria had a better overall survival than those with restrictive criteria (85% vs. 68%, respectively), suggesting that restrictive criteria were more predictive of prognosis than liberal criteria. In addition, patients treated for cytopenias had significantly worse overall survival (69%) compared to those treated for any other indication (97%, P < 0.0001). Patients with disease-related symptoms, progressive lymphocytosis, and extranodal involvement as isolated indications for treatment had similar overall survival to those with no indication for treatment. Our results demonstrate that a more restrictive approach to treatment initiation in CLL, as proposed by the BGCLL, better identifies patients with higher disease burden and poorer outcomes, while sparing others unnecessary therapy. Brazilian Registry of CLL–Brazilian Association of Hematology and Hemotherapy (ABHH)/ 10.13039/501100002322 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).